{"name":"Jounce Therapeutics, Inc.","slug":"jounce-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9ZMjdqOS1lOEFFbFpzNUQ4QUw3TTE4ZWYzX1lvUGZRMUxLdGl0SXR0dlh6eGFCOTU1YTNoRUwzQU1TeExUSkQySWF5NG5Vbm56aVR3?oc=5","date":"2025-09-16","type":"pipeline","source":"FirstWord Pharma","summary":"Lilly-backed Dualitas debuts with $65M to find 'highly differentiated' bispecifics - FirstWord Pharma","headline":"Lilly-backed Dualitas debuts with $65M to find 'highly differentiated' bispecifics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQWXlSdFUybXEyRjZOanNYZmdkdjBPWk1kOGFUZzZhdU1zZEY4Wk83aHJQdWxxSktDLTBDYTZBMmZnNFkzYUl0SDdLODVfOGx0Z05mcUhCejBna3dHMFdBZWRramdXWUNnZFFCMVlySkVwWnJ2UUdlaGFxY0x3Y3lhSmw2WVJnU3V0eVNnbExfTUJTR0ZCTGNUbXl4cEc2T1VsOGFVbkdB?oc=5","date":"2025-03-14","type":"deal","source":"Fierce Biotech","summary":"Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms - Fierce Biotech","headline":"Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxONk93NUl6OHRlQktmV2hiMEhHMXBxV3JrZ3N4UEJNNTNWQjJQX1gtUHBnSVkzUDE0QWMxZzVUeVprbnVGTFJWSkV5RHZvLWdoUk9GWFRsVERaSm5FZ2M4V3VHUGJFdVFmTkFjaU5kNmg5U2hpMXVQUVFTOWZyTEhraGtaVzRveTBBREdsc3RZdXY4NksyZWQzVUVwYXBjLU9xU3Z5T3p4MEx4SjNhUXBPX1NKUGlBQXVyWUZMMS1qeVFSbVNT?oc=5","date":"2025-02-12","type":"deal","source":"BW Healthcare World","summary":"Biotech Companies Redx Pharma, Jounce Therapeutics To Merge In USD 425 Mn Deal - BW Healthcare World","headline":"Biotech Companies Redx Pharma, Jounce Therapeutics To Merge In USD 425 Mn Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOU0FUNWVhNzQ1amI2N0ktYmsyWF90QzdoV09TaWZhTWkyUk5val93YTMyOTljbXJNSGNsLXBsZHpfb1U5Q2p6ZXB5T3FSeG5QN2lBbko4RjRXRzhTZUxLUnBLbWZRVEs5YkZnem1nN1hmWFRyUm9mYjZlYks0NFduLTRTWGFrTURhelNJMnMtcnJiQzdaTG5MSlNpNUlvcFlva09Wa0U2aU1VMHB4NWZr?oc=5","date":"2024-10-15","type":"pipeline","source":"Business Wire","summary":"Lucy Therapeutics Appoints Kim Drapkin as Board Chair - Business Wire","headline":"Lucy Therapeutics Appoints Kim Drapkin as Board Chair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNN2xudDFSaE1ucXo0aWRBbHo0SjNCQlBSZWRzWkE0dHdoZTVOQkdKV3ppNkgwamRNTFBuWS1lX21OQXlKaEJBWFhZckZmNUVPd1dRWmJHNW1heHAxSTA2OWV6WlR3dWltZC1hY0ZGaHhUWEQtYWRpY2owUEpMMGJHa1V3Q216Y3k1cG5FbWpMUi1ienltdU9xWmdKRHFTanhl?oc=5","date":"2023-12-04","type":"deal","source":"BioWorld News","summary":"Tang Capital’s Concentra offers $465M cash buyout of Lianbio - BioWorld News","headline":"Tang Capital’s Concentra offers $465M cash buyout of Lianbio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPdVJjeGFZSEdGVGtZQlB2bW9MNWFHWkRMWmp3TDNIV3h5X2hkUTNETTU1VGprYnhyNGJqT0JzS1hDc0RVVFNQcjR6Wjh3djNXQWZQM18ydE1lU2pfVUh6d3U2bVNOVUl1dkVzbFdQU1NsZUFKWmJma0ZxUERtRXN0WnV2Z0VMTE5Kb3o3N2ZJUUFrX3VmTFdRRWZ0NzFfSi1lVWx3QnRzbHdOUQ?oc=5","date":"2023-03-27","type":"pipeline","source":"The Business Journals","summary":"Jounce pivots, agrees to $96.5M acquisition by mysterious biotech - The Business Journals","headline":"Jounce pivots, agrees to $96.5M acquisition by mysterious biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOWTczaDRLeVh2RFBPX3Nrbm9HNmZrejNaVEgyLXZ1NDBwWGdXMXl0X01oWUp4NXl5OHJjT2MzNzd5NjExUDIwdmhCbzNiTWoyV1RZS1FjLXhSdmM2NWE3OXpkZFZTMkFTa2JkM1l2MUdSQ05kV2otT2ZHUm1jOXJfU3BRWUtXMXM0SkhLT2lWTQ?oc=5","date":"2023-03-15","type":"pipeline","source":"BioPharma Dive","summary":"Jounce gets rival takeover bid from company controlled by shareholder - BioPharma Dive","headline":"Jounce gets rival takeover bid from company controlled by shareholder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNRFdHeVBsdFR5ZDdPVWxpVkpDNGNzdlVXUmxrek5falcyeXVVRXQyTE4yMVkxZ1BURmZvc0FaLUpMRVVMN3VhaEZrZ1VWTGxUYzZ5dEJrVjNwQTU1VXV6dGZBckdBU09GbC1WbTNTdld6OUpHaWZMdkZVejFqdjBEY1NCSk5WNTV1NzhCelVGVzdobjRFeEFHSm12eXZ3UU1iMTAxbEgxckVtOWJSSjcyWkY1NkFoR0tlTkZYSXNYaVVUNW5uSGhUag?oc=5","date":"2023-02-23","type":"pipeline","source":"GlobeNewswire","summary":"Redx and Jounce Announce Recommended Business Combination - GlobeNewswire","headline":"Redx and Jounce Announce Recommended Business Combination","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPeV9BTGhMVlRzTmlORGJEbWZ1bC1DMnlWUUJFZEduZF9aM0NXVVMzNFlaNTFFVzFJTXEwMmptbnFxcDBkVXZoUWZtajRxNDhKQnV1TUl0UnctQXEtb1U1c2t5UmVZbnlVX05TZEhVYjh6eGJWTlktV3AzNFZNZlFTQXdsT2VDVFdPR0JsM01Mc1R4QTd4cmlLanJYWHQ?oc=5","date":"2023-02-23","type":"deal","source":"seekingalpha.com","summary":"Jounce stock soars ~35% on all-stock merger with Redx Pharma - seekingalpha.com","headline":"Jounce stock soars ~35% on all-stock merger with Redx Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOOWFRR0dndklIaTNSaXhFWlZmZUFPbTRDdU44TFNfTlpLYzBTQVdjM08yZU9ielQ3MjF1Mkpnb1Naak5FT2FiQ0NWNGs1bzFIcG9kcUFoblBLdm44bVBLd3ZaU0xNc3R6bDROUFEwckl3eGp2WkdHcjU2bmMtQ1dHNFJSako?oc=5","date":"2023-02-23","type":"pipeline","source":"pharmaphorum","summary":"Redx joins with Jounce to create cancer, fibrosis biotech - pharmaphorum","headline":"Redx joins with Jounce to create cancer, fibrosis biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxObW5OR0UydUowMHhIdldOR2dQTmNCajRYSFVXNzhyRGh0NVJUMjFaMEdQX05XTUNka0ZrRnRSXzgtMnpFUGdXbFdSY2hBWmc1ZVhDTlVfZU1abmlGU05rNzRBOFVvSjlRZEVHaG5teW10RGNERXJTZFVHRWdjNU5tdUhBTEpvRE5JbGhobUdMR1hMVHVxY3I1RkxKUHFiRWFTYW04?oc=5","date":"2022-12-29","type":"deal","source":"Reuters","summary":"Gilead buys out rights to cancer therapy from Jounce for $67 mln - Reuters","headline":"Gilead buys out rights to cancer therapy from Jounce for $67 mln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5qRlhBOFFGVDZrMGJYWi1QWEJPUjEzMUxTajMzZmVCRkdmVzgyYkNLdHlxR0gyTGd0RjRDRUxwSjFZV1hWdkl1V0hvZjdYVHgtWUhDWHJIZWhvMWFIMW82bFRLN004MTIxVFJJMVBsTUFoMlhjcFdNYzl3NXg?oc=5","date":"2022-08-30","type":"pipeline","source":"BioPharma Dive","summary":"Jounce’s latest setback dampens outlook for another cancer immunotherapy target - BioPharma Dive","headline":"Jounce’s latest setback dampens outlook for another cancer immunotherapy target","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}